Stocks met some mixed and selective profit-taking in recent days, but the S&P 500 and Nasdaq managed to close slightly higher while the Dow Jones industrials did not. All three major stock indexes were indicated to open marginally higher on Friday as well. It is very important to consider that earnings season is mostly looking rather strong so far. Stocks have also hit all-time highs in recent days.

Many investors still have not made portfolio changes during and after a very strong market in 2019. The markets now are treating a risk-on trade as being better than selling the news, despite being in overbought territory heading into earnings season. This is also an election year in which much is at stake, and strategists are by and large calling for single-digit percentage gains in 2020.

24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for traders and long-term investors alike. Some of the daily analyst calls cover stocks to buy, while some calls cover stocks to sell or to avoid.

We have provided these analyst calls in a quick-hit summary for easy reading, and additional comments and trading data have been added on many of the calls. The consensus analyst price targets and other valuation metrics are from the Refinitiv sell-side research service.

These are the top analyst upgrades, downgrades and initiations from Friday, January 24, 2020.

Apple Inc. (NASDAQ: AAPL) was reiterated as Outperform and the formal price target was lifted to $400 from $350 at Wedbush Securities, with the services and a 5G iPhone supercycle coming. While full details of that call are available, a firm named Rosenblatt Securities maintained its Sell rating on Apple and raised its target to $250 from $150 in a call that now removes the official “street-low” target price in the Refinitiv universe. The combination of these two calls should handily increase Apple’s consensus target price.

Applied Genetic Technologies Corp. (NASDAQ: AGTC) had been down as much as 33% on Thursday, but the end of day close was down by a less disastrous 15% at $8.37, after showing mixed achromatopsia data. Janney has reiterated its Outperform rating and with an $18 target price, after noting that the mixed achromatopsia data should not really affect valuations and that an update in the second half of 2020 should provide clarity to the situation.

Arvinas Inc. (NASDAQ: ARVN) was reiterated as Outperform and its target was raised to $60 from $39 (versus a $50.86 prior close) at Wedbush. The firm noted that initial efficacy data is due in the first half of 2020 for its lead Protac ARV-110 in anti-tumor activity.

BioNTech S.E. (NASDAQ: BNTX) was downgraded to Market Perform from Outperform at SVB Leerink. Its shares were down 5.6% at $36.70 on Thursday and down another 1.9% at $36.00 in Friday’s early indications.

Centene Corp. (NASDAQ: CNC) has seen its WellCare merger close, and SunTrust Robinson Humphrey reiterated its Buy rating and raised its target price to $85 from $77. Shares closed up almost 2% at $68.02 ahead of the call, with a $75.18 consensus target price.

Comcast Corp. (NASDAQ: CMCSA) was down 3.8% at $45.65 in Thursday’s post-earnings reaction, with a 52-week range of $34.67 to $47.74 and a consensus target price of $51.11. UBS downgraded it to Neutral from Buy with a $49 target price. SunTrust Robinson Humphrey reiterated its Buy rating and raised the target price to $53 from $49.

Electronic Arts Inc. (NASDAQ: EA) was reiterated as Outperform with a $118 target price (versus a $113.48 close) at Wedbush, with the firm noting that Star Wars is delivering and that it is well positioned for sustainable growth.

Epizyme Inc. (NASDAQ: EPZM) was reiterated as Outperform and its target price was raised to $30 from $24 (after a 4.7% gain to $26.72) at Wedbush, with the firm talking up its FDA approval of Tazverik for patients with epithelioid sarcoma and with higher-than-expected pricing. Its prior consensus target price was $23.25.

Exact Sciences Corp. (NASDAQ: EXAS) was named as the Bull of the Day at Zacks, which said that massive growth in Cologuard may be slowing but cancer detection is their game, with multiple targets in sight. Shares most recently closed at $92.18, with a consensus price target of $124.21.

Facebook Inc. (NASDAQ: FB) was reiterated as Outperform with a $250 target price (versus a $219.76 close) at Wedbush, with the firm calling for upside on the headline figures and growth from its monthly active users and from its daily active users.

GameStop Corp. (NYSE: GME) was again named as the Zacks Bear of the Day stock. The firm said that the business has been unable to adapt to the evolving economic landscape. Shares last closed at $4.62 and have a consensus price target of $4.45.

Intel Corp. (NASDAQ: INTC) traded up 0.9% to $63.32, but a classic “beat and” quarter with strong data center revenues had shares up close to 6.5% at $67.40 in the post-earnings reaction. Intel was last seen up closer to 5% at $66.50 ahead of Friday’s opening bell. Cowen maintained it as Market Perform and raised its target to $64 from $55. Wells Fargo maintained an Equal Weight rating and raised its target to $70 from $58. Loop Capital downgraded Intel to Sell from Hold with a $59 target price. Morgan Stanley reiterated its Overweight rating and raised its target price to $71 from $66.

Kimberly-Clark Corp. (NYSE: KMB) was maintained with a Sell rating at Citigroup, but the firm did raise its target price to $135 from $123 in the call. The consensus target price was $139.29, and the most recent close was at $144.65.

Matinas Biopharma Holdings Inc. (NASDAQ: MTNB) was started as Buy at SunTrust Robinson Humphrey, and the $3.00 target price compared with a $1.58 prior close. The firm sees Matinas growing rapidly, calling it the young fish in a big pond, with the omega-3 class of drugs being poised for significant growth ahead.

M&T Bank Corp. (NYSE: MTB) rose 5.25% to $170.37 in Thursday’s post-earnings trading reaction. Merrill Lynch raised it to Neutral from Underperform. Wedbush maintained its Neutral rating but raised its target to $174 from $169.

Pacira BioSciences Inc. (NASDAQ: PCRX) was started as Buy at SunTrust Robinson Humphrey, and the $60 target price compared with a $44.09 close. The firm sees continued Exparel momentum driving the shares.

PG&E Corp. (NYSE: PCG) closed up 9.5% at $13.73 on Thursday. UBS reiterated its Neutral rating, but the firm did raise its target price to $15 from $9. The shares were indicated up 3.3% at $14.10 on Friday.

Procter & Gamble Co. (NYSE: PG) was down 0.5%at $124.99 after the post-earnings reaction, but shares had traded as low as $123.65 after the news. Citigroup reiterated it as Buy and raised the target price to $143 from $138. SunTrust Robinson Humphrey reiterated its Hold rating.

SLM Corp. (NYSE: SLM) saw its shares rise by 29% to $11.75 on Thursday as its earnings showed a shift in capital management. Citigroup reiterated it as Buy and raised its target price to $14 from $11. It had a $13.09 consensus target price.

Take-Two Interactive Software Inc. (NASDAQ: TTWO) was downgraded to Neutral from Buy at MKM Partners, with the firm citing a lack of visibility in the game maker’s content pipeline.

Travelers Companies Inc. (NYSE: TRV) saw its shares fall 5% to $134.19 in its post-earnings reaction on Thursday, with a $137.94 consensus target price. Wells Fargo reiterated its Underweight rating and lowered its target price to $130 from $136.

WPX Energy Inc. (NYSE: WPX) was reiterated as Overweight and the target price was raised to $18 from $17 (versus a $12.50 close) at Wells Fargo.

Interest rates are falling once again, and we found five top Wall Street Buy-rated stocks that could be poised for a huge 2020.

Thursday’s top analyst upgrades and downgrades included Abbott Laboratories, Chevron, Cimarex Energy, DocuSign, General Electric, IBM, Micron Technology, Microsoft, Nvidia, Tesla and Western Digital.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.